Overview

• Lab studies showed the injectable gel released more than 90% of levodopa and 81% of carbidopa over seven days with minimal toxicity.
• The biodegradable formulation pairs FDA-approved PLGA with pH-sensitive Eudragit L-100 to achieve controlled week-long medication release.
• Researchers demonstrated that the drug can be administered subcutaneously or intramuscularly through a fine 22-gauge needle, avoiding surgical implants.
• An Australian patent application has been filed for the weekly Parkinson’s injection as researchers prepare for preclinical animal testing.
• The delivery platform could be adapted for other chronic conditions such as diabetes, cancer and chronic infections requiring sustained drug release.